StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Syndax Pharmaceuticals's total assets was $692.67M at Sep 30, 2026. For fiscal 2025 it was $529.71M, down 26.9% from the year before. Over ten years it grew 19.4% a year on average. The highest annual figure on record is $724.82M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$529.71M-26.9%
FY2024Dec 31, 2024$724.82M+18.3%
FY2023Dec 31, 2023$612.88M+23.3%
FY2022Dec 31, 2022$497.24M+10.6%
FY2021Dec 31, 2021$449.66M+49.6%
FY2020Dec 31, 2020$300.61M+373.2%
FY2019Dec 31, 2019$63.53M-24.3%
FY2018Dec 31, 2018$83.94M-38.8%
FY2017Dec 31, 2017$137.19M+25.8%
FY2016Dec 31, 2016$109.01M+21.3%
FY2015Dec 31, 2015$89.90M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$692.67M+25.5%
Q2 FY2026Jun 30, 2026$703.65M+18.0%
Q1 FY2026Mar 31, 2026$472.67M-26.2%
Q4 FY2025Dec 31, 2025$529.71M-26.9%
Q3 FY2025Sep 30, 2025$551.79M+29.6%
Q2 FY2025Jun 30, 2025$596.15M+25.0%
Q1 FY2025Mar 31, 2025$640.71M+18.0%
Q4 FY2024Dec 31, 2024$724.82M+18.3%
Q3 FY2024Sep 30, 2024$425.81M+6.7%
Q2 FY2024Jun 30, 2024$476.95M+10.6%
Q1 FY2024Mar 31, 2024$543.03M+18.1%
Q4 FY2023Dec 31, 2023$612.88M+23.3%
Q3 FY2023Sep 30, 2023$399.22M+11.0%
Q2 FY2023Jun 30, 2023$431.34M+6.1%
Q1 FY2023Mar 31, 2023$459.83M+8.9%
Q4 FY2022Dec 31, 2022$497.24M+10.6%
Q3 FY2022Sep 30, 2022$359.69M+50.2%
Q2 FY2022Jun 30, 2022$406.44M+54.5%
Q1 FY2022Mar 31, 2022$422.22M+51.0%
Q4 FY2021Dec 31, 2021$449.66M+49.6%
Q3 FY2021Sep 30, 2021$239.50M+33.6%
Q2 FY2021Jun 30, 2021$263.06M+36.6%
Q1 FY2021Mar 31, 2021$279.67M+166.0%
Q4 FY2020Dec 31, 2020$300.61M+373.2%
Q3 FY2020Sep 30, 2020$179.31M+134.8%
Q2 FY2020Jun 30, 2020$192.63M+120.4%
Q1 FY2020Mar 31, 2020$105.16M+5.8%
Q4 FY2019Dec 31, 2019$63.53M-24.3%
Q3 FY2019Sep 30, 2019$76.38M-20.8%
Q2 FY2019Jun 30, 2019$87.39M-17.1%
Q1 FY2019Mar 31, 2019$99.39M-17.1%
Q4 FY2018Dec 31, 2018$83.94M-38.8%
Q3 FY2018Sep 30, 2018$96.47M-22.5%
Q2 FY2018Jun 30, 2018$105.37M-21.8%
Q1 FY2018Mar 31, 2018$119.96M+22.8%
Q4 FY2017Dec 31, 2017$137.19M+25.8%
Q3 FY2017Sep 30, 2017$124.49M–
Q2 FY2017Jun 30, 2017$134.67M–
Q1 FY2017Mar 31, 2017$97.67M–
Q4 FY2016Dec 31, 2016$109.01M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?